Where Are The Biosimilars?
This article was originally published in RPM Report
Executive Summary
An abbreviated pathway for follow-on biologics was one of the biggest issues for biotech investors in the legislative debate over health care reform. Two years after enactment, FDA is still waiting for the first application.